Literature DB >> 26596949

Exposing a β-Lactamase "Twist": the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase.

Krisztina M Papp-Wallace1, Scott A Becka2, Magdalena A Taracila3, Marisa L Winkler4, Julian A Gatta2, Drew A Rholl5, Herbert P Schweizer6, Robert A Bonomo7.   

Abstract

Around the world, Burkholderia spp. are emerging as pathogens highly resistant to β-lactam antibiotics, especially ceftazidime. Clinical variants of Burkholderia pseudomallei possessing the class A β-lactamase PenI with substitutions at positions C69 and P167 are known to demonstrate ceftazidime resistance. However, the biochemical basis for ceftazidime resistance in class A β-lactamases in B. pseudomallei is largely undefined. Here, we performed site saturation mutagenesis of the C69 position and investigated the kinetic properties of the C69F variant of PenI from B. pseudomallei that results in a high level of ceftazidime resistance (2 to 64 mg/liter) when expressed in Escherichia coli. Surprisingly, quantitative immunoblotting showed that the steady-state protein levels of the C69F variant β-lactamase were ∼4-fold lower than those of wild-type PenI (0.76 fg of protein/cell versus 4.1 fg of protein/cell, respectively). However, growth in the presence of ceftazidime increases the relative amount of the C69F variant to greater than wild-type PenI levels. The C69F variant exhibits a branched kinetic mechanism for ceftazidime hydrolysis, suggesting there are two different conformations of the enzyme. When incubated with an anti-PenI antibody, one conformation of the C69F variant rapidly hydrolyzes ceftazidime and most likely contributes to the higher levels of ceftazidime resistance observed in cell-based assays. Molecular dynamics simulations suggest that the electrostatic characteristics of the oxyanion hole are altered in the C69F variant. When ceftazidime was positioned in the active site, the C69F variant is predicted to form a greater number of hydrogen-bonding interactions than PenI with ceftazidime. In conclusion, we propose "a new twist" for enhanced ceftazidime resistance mediated by the C69F variant of the PenI β-lactamase based on conformational changes in the C69F variant. Our findings explain the biochemical basis of ceftazidime resistance in B. pseudomallei, a pathogen of considerable importance, and suggest that the full repertoire of conformational states of a β-lactamase profoundly affects β-lactam resistance.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26596949      PMCID: PMC4750712          DOI: 10.1128/AAC.02073-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

1.  Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme.

Authors:  S Lin; M Thomas; D M Shlaes; S D Rudin; J R Knox; V Anderson; R A Bonomo
Journal:  Biochem J       Date:  1998-07-15       Impact factor: 3.857

2.  Exploring the role of a conserved class A residue in the Ω-Loop of KPC-2 β-lactamase: a mechanism for ceftazidime hydrolysis.

Authors:  Peter S Levitt; Krisztina M Papp-Wallace; Magdalena A Taracila; Andrea M Hujer; Marisa L Winkler; Kerri M Smith; Yan Xu; Michael E Harris; Robert A Bonomo
Journal:  J Biol Chem       Date:  2012-07-26       Impact factor: 5.157

3.  Understanding the molecular determinants of substrate and inhibitor specificities in the Carbapenemase KPC-2: exploring the roles of Arg220 and Glu276.

Authors:  Krisztina M Papp-Wallace; Magdalena A Taracila; Kerri M Smith; Yan Xu; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

4.  Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Authors:  David E Ehmann; Haris Jahić; Philip L Ross; Rong-Fang Gu; Jun Hu; Gunther Kern; Grant K Walkup; Stewart L Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

5.  Complementary roles of mutations at positions 69 and 242 in a class A beta-lactamase.

Authors:  R A Bonomo; C G Dawes; J R Knox; D M Shlaes
Journal:  Biochim Biophys Acta       Date:  1995-02-22

6.  Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.

Authors:  Krisztina M Papp-Wallace; Christopher R Bethel; Anne M Distler; Courtney Kasuboski; Magdalena Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

7.  Variations in ceftazidime and amoxicillin-clavulanate susceptibilities within a clonal infection of Burkholderia pseudomallei.

Authors:  I-Ching Sam; Kah Heng See; Savithri D Puthucheary
Journal:  J Clin Microbiol       Date:  2009-03-18       Impact factor: 5.948

8.  Site-directed mutagenesis at the active site of Escherichia coli TEM-1 beta-lactamase. Suicide inhibitor-resistant mutants reveal the role of arginine 244 and methionine 69 in catalysis.

Authors:  M Delaire; R Labia; J P Samama; J M Masson
Journal:  J Biol Chem       Date:  1992-10-15       Impact factor: 5.157

9.  A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand.

Authors:  Allen C Cheng; Direk Limmathurotsakul; Wirongrong Chierakul; Nongluk Getchalarat; Vanaporn Wuthiekanun; Dianne P Stephens; Nicholas P J Day; Nicholas J White; Wipada Chaowagul; Bart J Currie; Sharon J Peacock
Journal:  Clin Infect Dis       Date:  2007-06-15       Impact factor: 9.079

10.  Cloning of the class D beta-lactamase gene from Burkholderia pseudomallei and studies on its expression in ceftazidime-susceptible and -resistant strains.

Authors:  Pannika Niumsup; Vanaporn Wuthiekanun
Journal:  J Antimicrob Chemother       Date:  2002-10       Impact factor: 5.790

View more
  15 in total

1.  Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.

Authors:  Krisztina M Papp-Wallace; Scott A Becka; Elise T Zeiser; Nozomi Ohuchi; Maria F Mojica; Julian A Gatta; Monica Falleni; Delfina Tosi; Elisa Borghi; Marisa L Winkler; Brigid M Wilson; John J LiPuma; Michiyoshi Nukaga; Robert A Bonomo
Journal:  ACS Infect Dis       Date:  2017-03-30       Impact factor: 5.084

2.  Exploring the Landscape of Diazabicyclooctane (DBO) Inhibition: Avibactam Inactivation of PER-2 β-Lactamase.

Authors:  Melina Ruggiero; Krisztina M Papp-Wallace; Magdalena A Taracila; Maria F Mojica; Christopher R Bethel; Susan D Rudin; Elise T Zeiser; Gabriel Gutkind; Robert A Bonomo; Pablo Power
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

3.  Exploring the Role of the Ω-Loop in the Evolution of Ceftazidime Resistance in the PenA β-Lactamase from Burkholderia multivorans, an Important Cystic Fibrosis Pathogen.

Authors:  Krisztina M Papp-Wallace; Scott A Becka; Magdalena A Taracila; Elise T Zeiser; Julian A Gatta; John J LiPuma; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

4.  Probing the Mechanism of Inactivation of the FOX-4 Cephamycinase by Avibactam.

Authors:  Michiyoshi Nukaga; Krisztina M Papp-Wallace; Tyuji Hoshino; Scott T Lefurgy; Christopher R Bethel; Melissa D Barnes; Elise T Zeiser; J Kristie Johnson; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam.

Authors:  Melissa D Barnes; Christopher R Bethel; Jim Alsop; Scott A Becka; Joseph D Rutter; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

6.  "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates.

Authors:  Elise T Zeiser; Scott A Becka; Brigid M Wilson; Melissa D Barnes; John J LiPuma; Krisztina M Papp-Wallace
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

7.  In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species.

Authors:  Krisztina M Papp-Wallace; Adam B Shapiro; Scott A Becka; Elise T Zeiser; John J LiPuma; Douglas J Lane; Rekha G Panchal; John P Mueller; John P O'Donnell; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

8.  Antibiotic Resistance Markers in Burkholderia pseudomallei Strain Bp1651 Identified by Genome Sequence Analysis.

Authors:  Julia V Bugrysheva; David Sue; Jay E Gee; Mindy G Elrod; Alex R Hoffmaster; Linnell B Randall; Sunisa Chirakul; Apichai Tuanyok; Herbert P Schweizer; Linda M Weigel
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

9.  Prediction of Burkholderia pseudomallei DsbA substrates identifies potential virulence factors and vaccine targets.

Authors:  Ben Vezina; Guillaume A Petit; Jennifer L Martin; Maria A Halili
Journal:  PLoS One       Date:  2020-11-20       Impact factor: 3.240

10.  Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.

Authors:  Krisztina M Papp-Wallace; Melissa D Barnes; Jim Alsop; Magdalena A Taracila; Christopher R Bethel; Scott A Becka; David van Duin; Barry N Kreiswirth; Keith S Kaye; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.